To evaluate the effect of intrapulmonary percussive ventilation (IPV) by mouthpiece during noninvasive positive-pressure ventilation with helmet in patients with exacerbation of chronic obstructive pulmonary disease (COPD).
I t has been demonstrated that first-line intervention with noninvasive positive-pressure ventilation (NPPV) can reverse acute respiratory failure in a significant number of patients with exacerbation of chronic obstructive pulmonary disease (COPD), and NPPV can be considered the ventilatory mode of choice in selected patients experiencing COPD exacerbations (1) (2) (3) (4) (5) (6) (7) (8) .
Recently, a new helmet has been proposed to provide NPPV to these patients (9) . The patients treated with the helmet presented better tolerance and fewer complications in comparison to those treated with standard facial mask, but the value of PaCO 2 was constantly higher in the helmet group. The authors reported that the hypercapnia was not associated with helmet CO 2 rebreathing but probably was attributable to a less efficient reduction of the inspiratory effort during NPPV due to a partial dissipation of the inspiratory pressure in the soft part of the helmet, thus thwarting the patientmachine synchrony. They concluded that NPPV with helmet can be used for patients with less severe acute exacerbation of COPD. In those cases it would be preferable to apply NPPV by using a facial mask, and, indeed, a recent study supports this hypotheses (10) . On the other hand, the advantages of the helmet in clinical practice are evident in terms of comfort and tolerability (9) . Intrapulmonary percussive ventilation (IPV) delivers high-frequency mini-bursts of flow at the mouth superimposed on the spontaneous breathing pattern, thus associating convective flow (intermittent positive-pressure ventilation) with high-frequency oscillations (diffusive flow) and improving gas exchange and elimination of secretions. IPV has been used in patients with cystic fibrosis (11, 12) , Duchenne muscular dystrophy (13) , and atelectasis (14, 15) .
The role of physical and respiratory therapies in patients with severe acute exacerbation of COPD requiring NPPV is not clearly established. However, it has been recently demonstrated that physiotherapy benefit these patients (16) . Among the mucus clearance strategies based on high-frequency oscillation, IPV represents a potentially good but not well-explored technique. measured. All physiologic variables improved after IPV. At discharge from the intensive care unit, PaCO 2 was lower in the IPV group compared with the Phys and control groups (mean ؎ SD, 58 ؎ 5.4 vs. 64 ؎ 5.2 mm Hg, 67.4 ؎ 4.2 mm Hg, p < .01). PaO 2 /FIO 2 was higher in IPV (274 ؎ 15) than the other groups (Phys, 218 ؎ 34; control, 237 ؎ 20; p < .01). In the IPV group, time of noninvasive ventilation (hrs) (median, 25th-75th percentile: 61, 60 -71) and length of stay in the intensive care unit (days) (7, 6 -8) were lower than other groups (Phys, 89, 82-96; control, 87, 75-91; p < .01; and Phys, 9, 8 -9; control, 10, 9 -11; p < .01).
Conclusions: IPV treatment was feasible for all patients. Noninvasive positive-pressure ventilation by helmet associated with IPV reduces the duration of ventilatory treatment and intensive care unit stay and improves gas exchange at discharge from intensive care unit in patients with severe exacerbation of COPD. (Crit Care Med 2006; 34:2940-2945) KEY WORDS: noninvasive ventilation; helmet; chronic respiratory failure; pressure support ventilation; respiratory physiotherapy; intrapulmonary percussive ventilation Hence, in a prospective and controlled trial, we randomized 40 patients with acute exacerbation of COPD, treated with NPPV by helmet, into two different groups of mucus clearance strategies: IPV vs. physical and respiratory therapy. We assessed as the primary end point the feasibility of IPV and the effect of the first session of IPV on gas exchange immediately after discontinuation of the NPPV helmet. The second aim of the study was to investigate the clinical events (need of intubation, duration of supported ventilation, length of ICU stay, complications) connected to the time course of the exacerbation of COPD in two groups.
MATERIALS AND METHODS
Patients and Design of the Study. Forty consecutive adult patients admitted to the intensive care unit (ICU) of Cattinara Hospital from January to September 2003 with acute exacerbation of COPD were studied in the semirecumbent position. The diagnosis of COPD was made according to clinical history, physical examination, and chest radiography. The patients met the following criteria for NPPV: They were admitted to ICU within a maximum of 12 hrs of admission to the emergency department and were tachypneic with a respiratory rate of Ͼ25 breaths/min, a pH of 7.10 -7.35, and a PaCO 2 Ͼ50 mm Hg. Additional criteria for enrollment were those proposed by Brochard et al. (2) and included an exacerbation of dyspnea lasting Ͻ2 wks and at least two of the following: respiratory rate Ͼ30 breaths/min, PaO 2 Ͻ45 mm Hg, and arterial pH Ͻ7.35 after breathing at FIO 2 Ͻ0.35 for Ն10 mins. Exclusion criteria were a) a Glasgow Coma Scale score Ͻ8; b) failure of more than two additional organs; c) severe hemodynamic instability defined as systolic blood pressure Ͻ0 mm Hg; d) electrocardiogram instability with evidence of ischemia or significant ventricular arrhythmia; and e) requirement for sudden intubation for cardiopulmonary resuscitation. No patients received active humidification. The Acute Physiology and Chronic Health Evaluation II score was determined 24 hrs after the admission to the ICU.
At admission the patients were randomly divided into two groups of 20 patients each by another physician unaware of the study: a) those undergoing standard helmet-NPPV and respiratory physiotherapy (Phys group) and b) those who would receive helmet-NPPV and noninvasive IPV via a mouthpiece (IPV group). The randomization was provided by a computer software on a patient-by-patient basis.
As first-line treatment, all patients received helmet-NPPV and medical therapy (i.e., oxygen therapy, nebulized ␤ 2 -agonists, systemic corticosteroids, diuretics, and antibiotics as required). We used a helmet (CaStar; Starmed, Mirandola, Italy) provided with antiasphyxia mechanisms. The inflatable cushion at the level of the soft collar of the helmet avoided air leakage, which was further ensured by the increased adherence of the collar to the neck during the mounting up of inspiratory pressure. The other characteristics of the helmet were identical to those previously reported (9) . A 7200 Puritan-Bennett ventilator (Puritan-Bennett Corporation, Carlsbad, CA) delivered intermittent positive-pressure ventilation to the helmet with the initial settings of 15 cm H 2 O inspiratory positive airway pressure and 5 cm H 2 O of positive end-expiratory pressure in pressure support mode triggered by flow-by. The baseline pressure support level was raised in steps of 2 cm H 2 O to obtain patient comfort, reduce the respiratory rate to Ͻ30 breaths/ min (17) , and eliminate accessory muscle activity (18) . The flow trigger was used at 3-5 L/min with a basal flow of 15-20 L/min. FIO 2 was used to maintain a peripheral oxygen saturation Ͼ90% as measured by pulse oximetry (Viridia M3, Hewlett-Packard GmbH, Boeblingen, Germany). All patients were monitored with continuous electrocardiography and pulse oximetry and repeated measurements of arterial blood gases (Radiometer ABL 300, Copenhagen, Denmark) to adjust the ventilator setting.
After the first 2 hrs of NPPV, the pH level and the clinical status were used to decide the need for intubation: If dyspnea and pH remained unchanged in relation to the evaluation at the beginning of NPPV, the patients were intubated and ventilated and, thus, eliminated from the study; otherwise they continued under NPPV. In the latter condition the inspiratory pressure was adjusted according to the patient's tolerance to obtain a respiratory rate Ͻ25 breaths/min and the disappearance of accessory muscle activity, as evaluated by palpating the sternocleidomastoid muscle (18) . NPPV was delivered almost continuously in the first 24 hrs with short intervals of spontaneous breathing with oxygen supplementation and aerosol therapy.
In the second day, and henceforth, NPPV was used in a sequential mode according to Hilbert et al (4) . Periods of 3-4 hrs of ventilation were alternated with 2-3 hrs of spontaneous breathing with controlled oxygen therapy. Patients in the Phys group underwent a 25-to 30-min session of standard respiratory physiotherapy (chest clapping, mobilization and postural drainage, and expiration with the glottis open in the lateral posture, 10 mins each), whereas patients in the IPV group received two 25-to 30-min sessions of IPV (via a mouthpiece) with a IPV-1 Percussionator (Percussionaire Corporation, Sandpoint, ID) and a Phasitron DUO (Percussionaire Corporation). The patients breathed through a mouthpiece that delivered high-flow minibursts at rates of 225 cycles per minute. IPV was applied during spontaneous inspiration with a peak delivery pressure Ͻ40 cm H 2 O. During respiratory physiotherapy, the thera-pists were instructed to alert the physician when heart rate, mean arterial pressure, and respiratory rate changed Ͼ25% of the basal values and when severe dyspnea or peripheral oxygen saturation Ͻ85% was present. During IPV, hemodynamic status, respiratory rate, and peripheral oxygen saturation were continuously monitored. The patients were returned to NPPV when peripheral oxygen saturation was Ͻ85% or when respiratory rate became Ͼ30 breaths/min (4) .
Invasive mechanical ventilation was substituted for NPPV right after the initial session of NPPV or during sequential mode in the following circumstances: a) increase in respiratory rate and gas exchange deterioration; b) development of conditions requiring tracheal intubation to protect the airways; c) deterioration of neurologic status with a Glasgow Coma Scale score Ͻ8; d) intolerance to the helmet fixation stripes; and e) major agitation requiring sedation. The patients were intubated with a Rusch cuffed tracheal tube (inner diameter, 7.5-8.0 mm) and ventilated (7200 Puritan-Bennett Ventilator, Puritan-Bennett Corporation, Carlsbad, CA) in the semirecumbent position under pressure support ventilation with positive end-expiratory pressure.
In both groups of patients we determined duration of mechanical ventilation, length of ICU stay, need for tracheostomy, and ICU mortality rate. We evaluated the presence of a) pneumonia (a new lung infiltrate on the chest radiograph associated with at least two of the following conditions: fever, leukocytosis, or purulent sputum in which a Gram-negative stain showed one or more types of bacteria) not present at admission (nosocomial pneumonia); b) sepsis syndrome defined as positive blood cultures and fever of Ͼ39°C together with positive cultures from suspected sources; and c) metabolic complications (hyponatremia: Na Ͻ120 mmol/L or serum potassium levels Ͻ3 mmol/L or Ͼ6 mmol/L, alkalosis or metabolic acidosis, fasting hyperglycemia Ͼ160 mg/dL).
The criteria to determine when ventilator assistance was discontinued were the following: normal mental status, hemodynamic stability, respiratory rate Ͻ25 breaths/min, absence of activation of accessory muscles of respiration and paradoxical abdominal motion, arterial pH Ͼ7.33, PaCO 2 Ͻ70 mm Hg, PaO 2 Ͼ55 mm Hg, and FIO 2 Ͼ0.35 without ventilatory support. The patients were discharged from the ICU when NPPV was switched to oxygen therapy with FIO 2 Ͻ0. 35 for Ն24 hrs and the patients met the following criteria: cardiorespiratory stability, respiratory rate Ͻ20 breaths/min, pH Ͼ7.35, PaO 2 Ͼ55 mm Hg, PaCO 2 Ͻ70 mm Hg, and absence of fever, leukocytosis, purulent sputum, and metabolic complications. An independent clinical team not involved in the research protocol determined discharge.
Another group of 40 patients (controls) were selected from a population of patients admitted to the ICU in the period 2001-2003 with a diagnosis of respiratory failure due to acute exacerbation of COPD. They had the same criteria of enrollment, discontinuation of ventilation, and discharge from the ICU as the IPV and Phys groups. These patients were treated with facial mask NPPV delivered by the same ventilator and similar settings, underwent respiratory physiotherapy, and were clinically treated as those in the other two groups. The physician who selected the controls was not involved in the study and was not informed about the course of treatment. For each patient in groups IPV and Phys, one matching control was selected according to the following criteria: age within 10 yrs and severity of illness at admission as assessed by Acute Physiology and Chronic Health Evaluation II within 5 points of the treated patients; PaCO 2 and arterial pH at admission within 10 mm Hg and 0.05 points of the values of the treated patients; and PaO 2 /FIO 2 (during oxygen therapy by a Venturi mask) within 25 points of the treated patients. When matching each patient, we based the relative importance of each factor on the coefficients of priority attributed to PaCO 2 , pH, age, Acute Physiology and Chronic Health Evaluation II, and PaO 2 / FIO 2 . The patients' characteristics are listed in Tables 1 and 2 .
The investigation was approved by the local Ethics Committee, and informed consent was obtained from each individual or his or her next of kin.
Statistical Analysis. One-way analysis of variance was used to compare continuous variables among groups; when normality test failed (Kolmogorov-Smirnov test), Kruskal-Wallis nonparametric test was used. Chisquare test (or Fisher's exact test when appropriate) was applied for categorical data. Student's t-test for paired data (or Wilcoxon's nonparametric test) was used to compare prepost treatment. All statistical computations were performed with Sigma Stat 3.11 (Systat Software, Point Richmond, CA) statistical software.
The null hypothesis was rejected with ␣ ϭ .05. Table 1 shows the anthropometric and functional characteristics of COPD patients at admission to the ICU. No differences among the three groups were detected. Fourteen, 13, and 21 patients in the IPV, Phys, and control groups, respectively, were hypersecretive, that is, produced Ն30 mL of secretion per day. PaO 2 and PaCO 2 in steady state (not considered in the design of the study) were available for 18 patients of 20 in the IPV group, 17 patients of 20 in the Phys group, and 36 patients of 40 in control group. The mean (ϮSD) values of PaO 2 and PaCO 2 were 58 Ϯ 5 and 55 Ϯ 6 mm Hg in the IPV group, 57 Ϯ 4 and 54 Ϯ 5 mm Hg in the Phys group, and 59 Ϯ 5 and 56 Ϯ 6 mm Hg in the control group, respectively.
RESULTS
After the first 2 hrs under helmet plus NPPV, five patients from the Phys group, six from the IPV group, and 12 individuals using facial mask required intubation and mechanical ventilation. On the second day, different treatment strategies were applied to Phys and IPV groups; that is, the former received respiratory physiotherapy and the latter intrapulmonary percussive ventilation; the control group differed from the first solely on the interface between ventilator and airways (Phys group ϭ helmet; control group ϭ facial mask). Until discharge, two, one, and nine patients required intubation and mechanical ventilation (Phys, IPV, and control groups, respectively) because of impairment of gas exchange (two patients) and intolerance to either the helmet (two patients) or the mask (eight patients). Table 2 lists the physiologic variables determined when the patients were discharged from the ICU. The IPV group presented lower PaCO 2 and higher PaO 2 / FIO 2 than the other two groups, which were not different. Table 3 shows that IPV patients were discharged with a shorter duration of ventilatory assistance and stay in the ICU than the other two groups, whereas no differences were found in need of intubation and complications.
The mean values of pressure support ventilation and positive end-expiratory pressure were not different in the groups ( Phys, physiotherapy; IPV, intrapulmonary percussive ventilation; NS, not significant; RR, respiratory rate; Pa mean , mean arterial pressure; APACHE, Acute Physiology and Chronic Health Evaluation. a Mean, SD; b one-way analysis of variance; c median, 25th-75th percentile; d Kruskal-Wallis ranks test. Patients were randomized at admission to two groups: The Phys group underwent helmet and noninvasive positive pressure ventilation plus respiratory physiotherapy, the IPV group was submitted to helmet and noninvasive positive pressure ventilation plus IPV, and the control group was treated with noninvasive positive pressure ventilation with facial mask plus respiratory physiotherapy. Phys, physiotherapy; IPV, intrapulmonary percussive ventilation; NS, not significant; RR, respiratory rate; Pa mean mean arterial pressure; HR, heart rate. a Mean, SD; b one-way analysis of variance; c median, 25th-75th percentile; d Kruskal-Wallis ranks test. Significant differences in IPV group vs. the other groups. The Phys group underwent helmet and noninvasive positive pressure ventilation plus respiratory physiotherapy, the IPV group was submitted to helmet and noninvasive positive pressure ventilation plus IPV, and the control group was treated with noninvasive positive pressure ventilation with facial mask plus respiratory physiotherapy.
In all instances, IPV did not yield general complications as aerophagia, regurgitation, hemodynamic impairment, and hemorrhage. Additionally, pH, PaCO 2 , PaO 2 /FIO 2 , respiratory and heart rates, and mean arterial pressure improved significantly after the first section of IPV (Table 4 ).
DISCUSSION
The potential benefit of mucus clearance strategies by physical and respiratory therapies in the management of patients with severe acute exacerbation of COPD has not been clearly established (19) . In trials with patients under oxygen therapy or during invasive ventilation, these techniques were found ineffective and even detrimental (20 -22) . To our knowledge, no studies have reported ineffectiveness or detrimental effects of respiratory physiotherapy in COPD patients during noninvasive ventilation. Indeed, many works report an increase in gas exchange by mechanically assisted cough or other methods of mucus clearance during noninvasive ventilation (23) (24) (25) (26) .
Finally, Bellone et al. (16) demonstrated that physiotherapy was efficient in removing bronchial secretions in patients with acute exacerbation of COPD during noninvasive ventilation.
Although the application of NPPV by means of a helmet has been recently reported in the treatment of patients with acute exacerbations of COPD, it was concluded that the technique is feasible but less efficient in carbon dioxide elimination in comparison with NPPV and face mask (9) . However, we hypothesized that, since IPV improves gas exchange in lung disease such as cystic fibrosis (10 -12), Duchenne muscular dystrophy (13) , and atelectasis (14, 15) and improves secretion mobilization and clearance in COPD patients (27) , it could also be useful in the acute exacerbation of COPD in patients treated with helmet instead of face mask, which has been considered as the gold standard for treatment.
High-frequency oscillation is believed to improve mucus clearance by means of a variety of mechanisms (28) . Another important beneficial feature of IPV is the improvement in gas exchange, and differ-ent mechanisms exist to explain gas transport under these conditions (29 -32) . IPV would improve gas exchange as a result of both convective and diffusive mechanisms, possibly increasing the ventilation/perfusion relationship of the lung. Intrapulmonary percussive ventilation delivers high-frequency mini-bursts of flow at the mouth superimposed on the spontaneous breathing pattern. It thus associates convective flow (intermittent positive-pressure ventilation) with highfrequency oscillations (diffusive flow), as can be seen in Fig. 1 . IPV associates the positive aspects of NPPV with those of the high-frequency ventilation.
The use of NPPV and helmet in COPD patients was introduced by Antonelli et al (9) . They reported that 30.3% of their patients failed this technique. In our experiment, we found an overall value of 35%, a value close to that previously reported (9) . It must be stressed that the rate of failure was identical in both helmet groups. Finally, NPPV used with a facial mask yields a worse clinical outcome than the helmet in acute hypoxemic respiratory failure (33) ; we also verified in our facial mask ventilated control group a worse outcome in patients with exacerbation of COPD (21 of 40 patients), as shown in Table  2 . It can thus be suggested that the helmet-NPPV can be used as a first-line approach in COPD patients, keeping in mind that about one fourth of them will require an invasive approach (11 of 40 patients were intubated within 2 hrs).
To our knowledge, there is no previous study associating helmet-NPPV and IPV to treat acute bouts of COPD. Our data demonstrate that two daily sessions of IPV were able to improve the clinical conditions of the patients faster (less time under helmet-NPPV, shorter stay in the ICU; Table 3 ) and to a larger extent (smaller PaCO 2 and higher PaO 2 /FIO 2 ; Table 4 ) than the patients of Phys and control groups, which presented similar results.
Two mechanisms to facilitate mucus clearance by high-frequency oscillation have been proposed. First, there could be an increased mucus/flow interaction leading to a decrease in the mucus viscoelasticity (34) ; second, the transient changes in air flow with each highfrequency cycle could produce shearing at the air-mucus interface and provide a cough-like force to the mucus layer (32, 35) . Additionally, gas exchange could be improved by high-frequency oscillation as a result of a redistribution of lung volume by increasing the volume of air Fisher's exact test. Significant differences in IPV group in relation to the other groups. The Phys group underwent helmet and noninvasive positive pressure ventilation plus respiratory physiotherapy, the IPV group was submitted to helmet and noninvasive positive pressure ventilation plus IPV, and the control group was treated with noninvasive positive pressure ventilation with facial mask plus respiratory physiotherapy. distal to partially obstructed airways (29) and by increasing the homogeneity of distribution of perfusion and ventilation (36) . As an overall result, deadspace volume is reduced, CO 2 elimination increases, and work of breathing diminishes (36, 37) . We tested the efficacy of one session of IPV. For this purpose, physiologic variables were measured before and after a 30-min session of IPV. Table 4 depicts an improvement in all measured variables suggesting that IPV is a useful and safe therapy under the present experimental circumstances.
We did not measure the selected physiologic variables after conventional respiratory physiotherapy in the other group prospectively studied. This can be considered a potential limitation of the study, and the comparison would probably have brought more value to the modifications observed after the first session of IPV. Indeed, our aims were not to compare the responses to the first application of IPV and physiotherapy but to verify the feasibility of IPV during acute exacerbation of COPD and to compare the effects of daily sessions of IPV and physiotherapy during NIV on the clinical events (need of intubation, duration of supported ventila-tion, length of ICU stay, complications) connected to the time course of the exacerbation of COPD. In line with this approach, the missing measurements for the variables after conventional respiratory physiotherapy do not deprive us of information on the groups.
Antonelli et al. (9, 33) found an excellent tolerance to the helmet (no treatment failure) but reported 36% and 38% failure to facial mask. Under this point of view the helmet was shown to be the best interface between the patient and the ventilator. Our data demonstrated that two patients could not tolerate the helmet because of the stripes, whereas eight control patients were intubated for intolerance to the facial mask. Conversely, IPV treatment (twice a day) was well tolerated in all instances, and adverse effects were not found.
Finally, three patients in the IPV group and four in the Phys group had been previously admitted to the ICU. However, these admissions occurred at least 6 months before the present study was begun. Furthermore, we tested the duration of stay in the ICU for the patients who were in the ICU for the first time versus the three and four aforementioned patients, and no differences were detected.
CONCLUSIONS
In patients with acute exacerbation of COPD, the association of IPV and NPPV with helmet reduced the duration of the artificial ventilation, reduced ICU stay, and improved gas exchange.
